1. Chabner B, Wilson W, Supko J. Pharmacology and toxicity of antineoplastic drugs in Williams. Haematol. 7th edition. 2006, pp. 249–74.
2. Fernandez H. New trends in the standard of care for initial therapy of AML. Haematol. 30th edition. 2010, pp. 56–61.
3. Fenaux P, Gattermann N, Seymour JF, Hellström-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149(2):244–9. Epub 2010 Feb 5.
4. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130–8. Epub 2010 Apr 12.
5. Almeida AM, Pierdomenico F. Generalized skin reactions in patients with MDS and CMML treated with azacitidine: effective management with concomitant prednisolone. Leuk Res. 2012;36(9):e211–3. Epub 2012 May 22.